Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

V disease and is administered by intramuscular injection. The safety and efficacy of Synagis were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (less than or equal to 35 weeks gestational age), and children with hemodynamically significant congenital heart disease. The first dose of Synagis should be administered prior to commencement of the RSV season, which usually starts in the fall and runs through the spring. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.

Very rare cases (<1 per 100,000 patients) of anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. Cases of anaphylaxis were reported following re-exposure to Synagis and rare severe hypersensitivity reactions occurred on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reaction occurs, caution should be used on re-administration of Synagis.

In clinical trials, the most common adverse events occurring at least one percent more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever and rhinitis. Cyanosis and arrhythmia were seen in children with CHD.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... May 23, 2013  Omeros Corporation (NASDAQ: ... New Drug Application (IND) to evaluate OMS824 in ... Food and Drug Administration (FDA). OMS824 selectively inhibits ... of the brain linked to a wide range ... and schizophrenia. OMS824 has shown promising results in ...
Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4
... Nov. 14, 2011 Regado Biosciences, Inc., a privately ... with active control agents, announces one poster presentation ... Association (AHA) Scientific Sessions meeting on November 14, ... EST session.  All three presentations highlight results from ...
... Corporation ("the Company"), a leading international manufacturer, marketer, and ... today announced its 2011 third quarter financial results. ... For the third quarter of 2011, the ... of 7.8% versus net sales of $223.7 million in ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4Pregis Announces Third Quarter 2011 Financial Results 2Pregis Announces Third Quarter 2011 Financial Results 3Pregis Announces Third Quarter 2011 Financial Results 4Pregis Announces Third Quarter 2011 Financial Results 5Pregis Announces Third Quarter 2011 Financial Results 6Pregis Announces Third Quarter 2011 Financial Results 7Pregis Announces Third Quarter 2011 Financial Results 8Pregis Announces Third Quarter 2011 Financial Results 9Pregis Announces Third Quarter 2011 Financial Results 10Pregis Announces Third Quarter 2011 Financial Results 11Pregis Announces Third Quarter 2011 Financial Results 12
(Date:5/23/2013)... This news release is available in French . ... Montreal researchers have discovered a novel molecular mechanism that ... other diseases of abnormal growth. In the May 23 ... from the University of Montreal explain how they found ... or prevents cells from dividing. , "Cells normally monitor ...
(Date:5/23/2013)... Six innovative research projects have been awarded grants ... the nation's largest private nonprofit funder of Lyme disease medical ... epidemiology of, and treatment and cure for Lyme and ... support the innovative research being conducted by some of ... the field today,” said Harriet Kotsoris, MD, LRA’s Chief ...
(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Applied ... solutions, announced today that it has added support for ... IDE, the eiConsole for Healthcare. In addition to ... such as LLP, FTP, and Web Services, it now ... The Direct Protocol is a specification of the ...
(Date:5/23/2013)... During pregnancy both the health of ... medical treatments, especially medication. In July 2006, a ... prompted the FDA to warn about a potential link ... as persistent pulmonary hypertension and other malformations (i). ... (SSRI) drugs. SSRI antidepressants are widely prescribed to ...
(Date:5/23/2013)... Each month Dwell magazine is filled ... and electric cars. Nowhere in America are these pages more ... car capital. Thankfully this June, Green Car Journal is bringing ... to Dwell on Design 2013 ( http://www.dwellondesign.com ), ... two days of Dwell on Design, June 21-22, attendees and ...
Breaking Medicine News(10 mins):Health News:Scientists discover how rapamycin slows cell growth 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 2Health News:Six Investigators Awarded Lyme Research Alliance Grants 3Health News:Six Investigators Awarded Lyme Research Alliance Grants 4Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5
... ,Time is Brain, SEATTLE, Nov. 14 On ... to activate an advanced telemedicine system,in the emergency rooms ... real-time, 24/7 link between ER physicians and stroke specialists ... Stroke,Program is based. The Swedish TeleStroke Program is ...
... Pa., Nov. 14 Escalon Medical Corp.,(Nasdaq: ESMC ... ended,September 30, 2007. For the first quarter of ... 4% decrease from the $7,168,160, reported in the prior,year ... at the,Company,s Sonomed and Vascular business units, which decreased ...
... Passion for Healthcare, MIAMI, Nov. 14 ... healthcare providers funded by,MTS Health Investors and Oaktree ... E. Burke III to the position of President ... experience to Novis,Pharmaceuticals, with extensive functional expertise in ...
... for November 20, NAPA, Calif., Nov. 14 ... company engaged in the,study of senescense, the science of ... today announced financial results for the,quarter ended September 30, ... $469,000 compared to,$2,027,000 for the same period in the ...
... - Now Families Can Breathe Easier During Cold and ... Nature,s Baby Organics,manufacturers of the finest and purest natural ... Ah-Choo! Chest Rub. Ah-Choo! Chest Rub was,created to bring ... common cold viruses and influenza. "With the unavoidable ...
... NEW YORK, NY November 14, 2007 The ... announced today that they are joining together to create ... of research into drugs and therapies to cure diabetes ... can measure the progress of disease and the effectiveness ...
Cached Medicine News:Health News:Lifesaving TeleStroke Technology Linked to Swedish 2Health News:Lifesaving TeleStroke Technology Linked to Swedish 3Health News:Lifesaving TeleStroke Technology Linked to Swedish 4Health News:Lifesaving TeleStroke Technology Linked to Swedish 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 2Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 2Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: